Background: Obesity is a risk factor for renal cell carcinoma (RCC). Plasma levels of adiponectin, a hormone secreted solely by adipocytes, inversely correlate with adverse prognostic factors in RCC. Since the volume of the metabolically active visceral adipose tissue (VAT) better reflects obesity associated morbidity than body mass index (BMI), we measured and correlated it to adiponectin levels and disease characteristics in patients with clear cell RCC (ccRCC). Patients and Methods: Visceral and subcutaneous adipose tissues were measured using preoperative CT scans in 25 ccRCC patients who had no previous history of other cancers, diabetes or impaired renal function. Tissue at fat density was separated into subcutaneous and visceral components and the pixels were summed across 3 transverse slices (upper aspect of the L2 vertebral body, the umbilicus and the anterior superior iliac spine) to create a surrogate score of percentage of VAT (visceral fat area/visceral plus subcutaneous fat area). This score was correlated to preoperative fasting plasma adiponectin levels, tumor size, grade, presence of metastasis and BMI by univariate and multivariate linear regression analysis. Results: BMI correlated strongly with total but not visceral fat. Percentage of VAT correlated inversely with plasma adiponectin levels (p < 0.05) and directly with the presence of metastasis (p < 0.05) but not with grade. BMI did not predict either. Conclusion: Visceral obesity is associated with lower levels of plasma adiponectin and also appears to be associated with metastatic disease in ccRCC. CT measurements of percentage of VAT may help in preoperative prognostication of ccRCC patients.

Keywords:
Adiponectin, Obesity, Renal cell cancer, Visceral fat
This content is only available via PDF.
© 2008 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.